The effects of paroxetine on rat isolated vas deferens. 2003

Ersin Yaris, and Murat Kesim, and Mine Kadioglu, and Nuri Ihsan Kalyoncu, and Cunay Ulku, and Rasin Ozyavuz
Department of Pharmacology, School of Medicine, Karadeniz Technical University, TR-61187 Trabzon, Turkey. eyaris@meds.ktu.edu.tr

The aim of the present study is to evaluate whether paroxetine (a selective serotonin re-uptake inhibitor) can modify the contractile responses of isolated vas deferens. Some contractile agents, potassium chloride (KCl), adenosine 5'-triphosphate (ATP), noradrenaline (NA), and electrical field stimulation (EFS) caused contractions both in epididymal and prostatic portions of vas deferens. Paroxetine (PX) in concentrations 10(-7) and 10(-6)M potentiated the contractions to KCl and ATP only in epididymal portion but in higher concentrations (10(-5) and 10(-4)M) inhibited the responses in both portions. NA responses were inhibited by PX in all concentrations used, both in prostatic and epididymal portions. Prazosin (PR), an alpha adrenergic receptor blocking agent, inhibited PX-induced potentiation observed for higher concentrations of KCl. PR also inhibited PX-induced potentiation on the responses to ATP in epididymal portion. Pretreatment with PX (10(-7) to 10(-6)M) increased the contractions to EFS but in 10(-5) and 10(-4)M concentrations inhibited them. Even though the preparations were washed out, the inhibited responses of contractile agents could not be restored. After a washout period for PX, when Bay K 8644 (calcium channel activator) was added to the bath medium, the contractile responses to KCl were partially restored. In calcium-free medium, KCl caused contractions in concentrations higher than 80 mM with lower amplitudes which were not affected by PX. Reserpinization did not change the inhibitory pattern of PX's effect on exogenously applied NA in all concentrations tested. In reserpinized rats, the potentiation caused by PX in exogenously applied ATP responses was not observed. In conclusion, we can say that PX has two different effects: inhibition and potentiation of contractions to various agonists. The inhibitory effect of the drug can be explained by a calcium channel blocking activity. The potentiating effect of the drug is mainly related to its presynaptic action, such as NA re-uptake inhibitory effect.

UI MeSH Term Description Entries
D008297 Male Males
D009119 Muscle Contraction A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments. Inotropism,Muscular Contraction,Contraction, Muscle,Contraction, Muscular,Contractions, Muscle,Contractions, Muscular,Inotropisms,Muscle Contractions,Muscular Contractions
D009130 Muscle, Smooth Unstriated and unstriped muscle, one of the muscles of the internal organs, blood vessels, hair follicles, etc. Contractile elements are elongated, usually spindle-shaped cells with centrally located nuclei. Smooth muscle fibers are bound together into sheets or bundles by reticular fibers and frequently elastic nets are also abundant. (From Stedman, 25th ed) Muscle, Involuntary,Smooth Muscle,Involuntary Muscle,Involuntary Muscles,Muscles, Involuntary,Muscles, Smooth,Smooth Muscles
D009638 Norepinephrine Precursor of epinephrine that is secreted by the ADRENAL MEDULLA and is a widespread central and autonomic neurotransmitter. Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers, and of the diffuse projection system in the brain that arises from the LOCUS CERULEUS. It is also found in plants and is used pharmacologically as a sympathomimetic. Levarterenol,Levonorepinephrine,Noradrenaline,Arterenol,Levonor,Levophed,Levophed Bitartrate,Noradrenaline Bitartrate,Noradrénaline tartrate renaudin,Norepinephrin d-Tartrate (1:1),Norepinephrine Bitartrate,Norepinephrine Hydrochloride,Norepinephrine Hydrochloride, (+)-Isomer,Norepinephrine Hydrochloride, (+,-)-Isomer,Norepinephrine d-Tartrate (1:1),Norepinephrine l-Tartrate (1:1),Norepinephrine l-Tartrate (1:1), (+,-)-Isomer,Norepinephrine l-Tartrate (1:1), Monohydrate,Norepinephrine l-Tartrate (1:1), Monohydrate, (+)-Isomer,Norepinephrine l-Tartrate (1:2),Norepinephrine l-Tartrate, (+)-Isomer,Norepinephrine, (+)-Isomer,Norepinephrine, (+,-)-Isomer
D011189 Potassium Chloride A white crystal or crystalline powder used in BUFFERS; FERTILIZERS; and EXPLOSIVES. It can be used to replenish ELECTROLYTES and restore WATER-ELECTROLYTE BALANCE in treating HYPOKALEMIA. Slow-K,Chloride, Potassium
D012110 Reserpine An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use. Raunervil,Raupasil,Rausedil,Rausedyl,Serpasil,Serpivite,V-Serp,V Serp
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D004558 Electric Stimulation Use of electric potential or currents to elicit biological responses. Stimulation, Electric,Electrical Stimulation,Electric Stimulations,Electrical Stimulations,Stimulation, Electrical,Stimulations, Electric,Stimulations, Electrical

Related Publications

Ersin Yaris, and Murat Kesim, and Mine Kadioglu, and Nuri Ihsan Kalyoncu, and Cunay Ulku, and Rasin Ozyavuz
April 1978, British journal of pharmacology,
Ersin Yaris, and Murat Kesim, and Mine Kadioglu, and Nuri Ihsan Kalyoncu, and Cunay Ulku, and Rasin Ozyavuz
July 1979, Archives internationales de pharmacodynamie et de therapie,
Ersin Yaris, and Murat Kesim, and Mine Kadioglu, and Nuri Ihsan Kalyoncu, and Cunay Ulku, and Rasin Ozyavuz
July 1980, British journal of pharmacology,
Ersin Yaris, and Murat Kesim, and Mine Kadioglu, and Nuri Ihsan Kalyoncu, and Cunay Ulku, and Rasin Ozyavuz
January 1978, General pharmacology,
Ersin Yaris, and Murat Kesim, and Mine Kadioglu, and Nuri Ihsan Kalyoncu, and Cunay Ulku, and Rasin Ozyavuz
December 1982, British journal of pharmacology,
Ersin Yaris, and Murat Kesim, and Mine Kadioglu, and Nuri Ihsan Kalyoncu, and Cunay Ulku, and Rasin Ozyavuz
November 1987, Japanese journal of pharmacology,
Ersin Yaris, and Murat Kesim, and Mine Kadioglu, and Nuri Ihsan Kalyoncu, and Cunay Ulku, and Rasin Ozyavuz
April 1963, British journal of pharmacology and chemotherapy,
Ersin Yaris, and Murat Kesim, and Mine Kadioglu, and Nuri Ihsan Kalyoncu, and Cunay Ulku, and Rasin Ozyavuz
April 1982, The Journal of pharmacy and pharmacology,
Ersin Yaris, and Murat Kesim, and Mine Kadioglu, and Nuri Ihsan Kalyoncu, and Cunay Ulku, and Rasin Ozyavuz
January 1981, British journal of pharmacology,
Ersin Yaris, and Murat Kesim, and Mine Kadioglu, and Nuri Ihsan Kalyoncu, and Cunay Ulku, and Rasin Ozyavuz
January 1979, General pharmacology,
Copied contents to your clipboard!